Titre : Déficit en IgG

Déficit en IgG : Questions médicales fréquentes

Termes MeSH sélectionnés :

Early Detection of Cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Déficit en IgG : Questions médicales les plus fréquentes", "headline": "Déficit en IgG : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Déficit en IgG : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-26", "dateModified": "2025-04-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Déficit en IgG" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Dysgammaglobulinémie", "url": "https://questionsmedicales.fr/mesh/D004406", "about": { "@type": "MedicalCondition", "name": "Dysgammaglobulinémie", "code": { "@type": "MedicalCode", "code": "D004406", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20.673.430" } } }, "about": { "@type": "MedicalCondition", "name": "Déficit en IgG", "alternateName": "IgG Deficiency", "code": { "@type": "MedicalCode", "code": "D017099", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "James C Barton", "url": "https://questionsmedicales.fr/author/James%20C%20Barton", "affiliation": { "@type": "Organization", "name": "University of Alabama at Birmingham, Birmingham, AL, USA. bartonjames336@gmail.com." } }, { "@type": "Person", "name": "Luigi F Bertoli", "url": "https://questionsmedicales.fr/author/Luigi%20F%20Bertoli", "affiliation": { "@type": "Organization", "name": "Southern Iron Disorders Center, Birmingham, AL, USA." } }, { "@type": "Person", "name": "Ronald T Acton", "url": "https://questionsmedicales.fr/author/Ronald%20T%20Acton", "affiliation": { "@type": "Organization", "name": "Southern Iron Disorders Center, Birmingham, AL, USA." } }, { "@type": "Person", "name": "Jackson C Barton", "url": "https://questionsmedicales.fr/author/Jackson%20C%20Barton", "affiliation": { "@type": "Organization", "name": "Southern Iron Disorders Center, Birmingham, Alabama, United States of America." } }, { "@type": "Person", "name": "Stacy Hall", "url": "https://questionsmedicales.fr/author/Stacy%20Hall", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36153587", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12957-022-02766-0" } }, { "@type": "ScholarlyArticle", "name": "Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer.", "datePublished": "2022-09-13", "url": "https://questionsmedicales.fr/article/36098904", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jcla.24692" } }, { "@type": "ScholarlyArticle", "name": "Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer.", "datePublished": "2022-09-08", "url": "https://questionsmedicales.fr/article/36088216", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jgo.2022.08.020" } }, { "@type": "ScholarlyArticle", "name": "Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.", "datePublished": "2022-07-15", "url": "https://questionsmedicales.fr/article/35856081", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s43856-022-00155-y" } }, { "@type": "ScholarlyArticle", "name": "Early Mortality among Patients with Head and Neck Cancer Diagnosed in Thuringia, Germany, between 1996 and 2016-A Population-Based Study.", "datePublished": "2022-06-24", "url": "https://questionsmedicales.fr/article/35804871", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/cancers14133099" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système immunitaire", "item": "https://questionsmedicales.fr/mesh/D007154" }, { "@type": "ListItem", "position": 3, "name": "Déficits immunitaires", "item": "https://questionsmedicales.fr/mesh/D007153" }, { "@type": "ListItem", "position": 4, "name": "Dysgammaglobulinémie", "item": "https://questionsmedicales.fr/mesh/D004406" }, { "@type": "ListItem", "position": 5, "name": "Déficit en IgG", "item": "https://questionsmedicales.fr/mesh/D017099" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Déficit en IgG - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Déficit en IgG", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Déficit en IgG", "description": "Comment diagnostique-t-on un déficit en IgG ?\nQuels tests sont utilisés pour évaluer les IgG ?\nLes symptômes aident-ils au diagnostic ?\nLe déficit en IgG est-il héréditaire ?\nQuel spécialiste consulte-t-on pour ce déficit ?", "url": "https://questionsmedicales.fr/mesh/D017099?mesh_terms=Early+Detection+of+Cancer&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Déficit en IgG", "description": "Quels sont les symptômes courants du déficit en IgG ?\nLes infections sont-elles plus graves ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLe déficit en IgG cause-t-il des allergies ?\nComment le déficit en IgG affecte-t-il la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D017099?mesh_terms=Early+Detection+of+Cancer&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Déficit en IgG", "description": "Comment prévenir les infections chez ces patients ?\nLes vaccinations sont-elles efficaces ?\nFaut-il éviter certains environnements ?\nL'alimentation joue-t-elle un rôle ?\nLe stress affecte-t-il le système immunitaire ?", "url": "https://questionsmedicales.fr/mesh/D017099?mesh_terms=Early+Detection+of+Cancer&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Déficit en IgG", "description": "Quels traitements sont disponibles pour le déficit en IgG ?\nLes antibiotiques sont-ils nécessaires ?\nY a-t-il des effets secondaires aux traitements ?\nLe traitement est-il à vie ?\nDes vaccins sont-ils recommandés ?", "url": "https://questionsmedicales.fr/mesh/D017099?mesh_terms=Early+Detection+of+Cancer&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Déficit en IgG", "description": "Quelles complications peuvent survenir ?\nLe déficit en IgG augmente-t-il le risque de cancer ?\nLes maladies auto-immunes sont-elles fréquentes ?\nComment gérer les complications ?\nLes complications affectent-elles la vie quotidienne ?", "url": "https://questionsmedicales.fr/mesh/D017099?mesh_terms=Early+Detection+of+Cancer&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Déficit en IgG", "description": "Quels sont les facteurs de risque du déficit en IgG ?\nL'âge influence-t-il le risque ?\nLes maladies chroniques sont-elles un facteur ?\nLe sexe joue-t-il un rôle ?\nLes traitements immunosuppresseurs augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D017099?mesh_terms=Early+Detection+of+Cancer&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on un déficit en IgG ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par des tests sanguins mesurant les niveaux d'IgG." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les IgG ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests d'immunoglobulines sériques et les tests de réponse vaccinale sont utilisés." } }, { "@type": "Question", "name": "Les symptômes aident-ils au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des infections récurrentes peuvent indiquer un déficit en IgG." } }, { "@type": "Question", "name": "Le déficit en IgG est-il héréditaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Il peut être héréditaire ou acquis, nécessitant une évaluation génétique." } }, { "@type": "Question", "name": "Quel spécialiste consulte-t-on pour ce déficit ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un immunologiste est le spécialiste à consulter pour un déficit en IgG." } }, { "@type": "Question", "name": "Quels sont les symptômes courants du déficit en IgG ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des infections fréquentes, fatigue et inflammation." } }, { "@type": "Question", "name": "Les infections sont-elles plus graves ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections peuvent être plus graves et plus fréquentes chez ces patients." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à surveiller ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Surveillez les infections respiratoires, sinusites et gastro-intestinales fréquentes." } }, { "@type": "Question", "name": "Le déficit en IgG cause-t-il des allergies ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Il peut y avoir une association avec des allergies, mais ce n'est pas systématique." } }, { "@type": "Question", "name": "Comment le déficit en IgG affecte-t-il la qualité de vie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Il peut réduire la qualité de vie en raison d'infections fréquentes et de fatigue." } }, { "@type": "Question", "name": "Comment prévenir les infections chez ces patients ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne hygiène, des vaccinations et un suivi médical régulier sont essentiels." } }, { "@type": "Question", "name": "Les vaccinations sont-elles efficaces ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations peuvent aider à prévenir certaines infections, mais pas toutes." } }, { "@type": "Question", "name": "Faut-il éviter certains environnements ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, éviter les foules et les personnes malades peut réduire le risque d'infection." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut soutenir le système immunitaire, mais ne remplace pas le traitement." } }, { "@type": "Question", "name": "Le stress affecte-t-il le système immunitaire ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut affaiblir le système immunitaire et augmenter le risque d'infections." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour le déficit en IgG ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des immunoglobulines intraveineuses ou sous-cutanées." } }, { "@type": "Question", "name": "Les antibiotiques sont-ils nécessaires ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antibiotiques peuvent être prescrits pour traiter les infections récurrentes." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des réactions allergiques et des douleurs au site d'injection." } }, { "@type": "Question", "name": "Le traitement est-il à vie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, le traitement est à vie pour maintenir des niveaux d'IgG adéquats." } }, { "@type": "Question", "name": "Des vaccins sont-ils recommandés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des vaccins peuvent être recommandés pour prévenir certaines infections." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections chroniques et des maladies auto-immunes." } }, { "@type": "Question", "name": "Le déficit en IgG augmente-t-il le risque de cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Il existe un risque accru de certains cancers, mais cela nécessite des études supplémentaires." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles fréquentes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent développer des maladies auto-immunes en raison d'un déficit immunitaire." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite un suivi médical régulier et un traitement approprié." } }, { "@type": "Question", "name": "Les complications affectent-elles la vie quotidienne ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent limiter les activités quotidiennes et nécessiter des soins constants." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque du déficit en IgG ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des infections virales et des maladies auto-immunes." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque peut augmenter avec l'âge, surtout chez les personnes âgées." } }, { "@type": "Question", "name": "Les maladies chroniques sont-elles un facteur ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies chroniques comme le diabète peuvent augmenter le risque de déficit en IgG." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent que les hommes peuvent être plus à risque que les femmes." } }, { "@type": "Question", "name": "Les traitements immunosuppresseurs augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements immunosuppresseurs peuvent augmenter le risque de déficit en IgG." } } ] } ] }

Sources (10000 au total)

Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.

Pylorus-preserving gastrectomy (PPG) is a function-preserving surgery for the treatment of early gastric cancer (EGC) in the middle third of the stomach. According to the literature reports, PPG decre... The protocol was registered in PROSPERO under number CRD42022304677. Databases including PubMed, Embase, Web of Science, and the Cochrane Register of Controlled Trials were searched before February 21... A total of 4500 patients from 16 studies were included. Compared with the CDG group, the PPG group had fewer lymph nodes harvested (WMD= -3.09; 95% CI -4.75 to -1.43; P < 0.001). Differences in the nu... The meta-analysis of existing evidence demonstrated that the survival outcomes of PPG may be comparable to those of CDG. However, fewer lymph nodes at stations in No. 5, No. 6, No. 9, and No. 11p were...

Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer.

The sensitivity and specificity of current biomarkers for gastric cancer were insufficient. The aim of the present study was to screen novel biomarkers and determine the diagnostic values of ornithine... With stable isotope tags, we labelled an initial discovery group of four paired gastric cancer tissue samples and identified with LC-ESI-MS/MS. A validation group of 159 gastric cancer samples and 30 ... Four hundred and thirty one proteins were found differentially expressed in gastric cancer tissues. Of these proteins, OAT and CPS1 were found over-expressed in gastric cancer patients, with sensitivi... The present findings indicated a tight correlation between the co-expression of OAT and CPS1 and the histological grade, local invasion, and TNM stages of gastric cancer. Therefore, OAT and CPS1 might...

Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer.

Among women with early-stage endometrial cancer (EC), age, stage, grade, and histology are used to determine fitness for adjuvant radiation therapy (RT) administration. We examined non-cancer factors ... Using data from the Surveillance Epidemiology and End Results cancer registry program linked with Medicare claims, we identified 25,654 women (aged ≥66 years) diagnosed with first primary stage I-II E... Adjuvant RT was less commonly administered to Asian American and Pacific Islander patients than non-Hispanic White patients (Prevalence ratio [PR], 0.84; 95% confidence interval [CI], 0.73 to 0.97). C... Findings suggest that various non-cancer factors affect the delivery of adjuvant RT to older women with early-stage EC in real-world oncology practice. Advancing our understanding of factors associate...

Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.

Treatment for metastatic colorectal cancer patients beyond the second line remains challenging, highlighting the need for early phase trials of combination therapies for patients who had disease progr... MORPHEUS-CRC is an umbrella, multicenter, open-label, phase Ib/II, randomized, controlled trial (NCT03555149), with active experimental arms ongoing. Patients enrolled were assigned to a control arm (... The experimental arm showed no efficacy signal, yet a well-tolerated safety profile in the MORPHEUS-CRC trial. Treatment effects estimated in hybrid control design were comparable to those in the MORP... Hybrid control provides comparable treatment-effect estimates with generally improved precision, and thus can be of value to inform early-phase clinical development in metastatic colorectal cancer....

Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.

Early biochemical recurrence (eBCR) indicated a high risk for potential recurrence and metastasis in prostate cancer. The N6-methyladenosine (m6A) methylation modification played an important role in ... Pearson correlation analysis was first conducted to explore m6A lncRNAs and univariate Cox regression analysis was further performed to identify m6A lncRNAs of prognostic roles for predicting eBCR in ... Five hundred and thirty-eighth m6A lncRNAs were searched out through Pearson correlation analysis and 25 out of 538 m6A lncRNAs were identified to pose prediction roles for eBCR in prostate cancers. A... The m6A lncRNA signature in this study could be utilized to efficiently predict eBCR occurrence, various clinical characteristic and immune microenvironment for prostate cancer....

MRI characteristics of breast edema for assessing axillary lymph node burden in early-stage breast cancer: a retrospective bicentric study.

To investigate whether breast edema characteristics at preoperative T2-weighted imaging (T2WI) could help evaluate axillary lymph node (ALN) burden in patients with early-stage breast cancer.... This retrospective study included women with clinical T1 and T2 stage breast cancer and preoperative MRI examination in two independent cohorts from May 2014 to December 2020. Low (< 3 LNs+) and high ... A total of 1092 patients were included in this study. BES was identified as the independent predictor of pALN burden in primary (n = 677) and validation (n = 415) cohorts. The analysis using MRI-ALN s... In individuals with early-stage breast cancer, preoperative MRI characteristics of breast edema could be a promising predictor for pALN burden, which may aid in treatment planning.... • In this retrospective study of 1092 patients with early-stage breast cancer from two cohorts, the MRI characteristic of breast edema has independent and additive predictive value for assessing axill...

A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis.

To evaluate the value of combined detection of serum CA125, CA199, and HE4 in the diagnosis of ovarian cancer.... Relevant articles retrieved from PubMed, Elsevier Science, Springer, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were screened strictly according to inclusion and exclus... The results of meta-analysis showed that there was a statistical difference in diagnostic specificity analysis of CA125 (OR = 1.91, 95% CI (1.58, 2.32),... In the clinical assisted diagnosis of ovarian cancer, combined detection of CA125, CA199, and HE4 has the stronger discriminant ability and higher accuracy than single detection of CA125, which can im...

BMI increase during early childhood in boys with cystic fibrosis and early adrenarche.

Increase in body mass index (BMI) in early childhood (1-6 years) was found to be a contributing factor for impaired final height in boys with Cystic Fibrosis (CF). Early adrenarche (before age 9 years... Boys with CF, aged 8-9 years, visiting the CF expertize center Utrecht were included. Since 2018, anthropomorphic, pubertal and endocrine data were collected. Early adrenarche in boys was defined as a... Thirteen boys (mean age 8.55 ± 0.27 years) were enrolled. The median (IQR) DHEAS-level was 1.3 µmol/L (0.71-2.40). Eight boys (61.5%) had an early rise in DHEAS-levels ≥ 1 µmol/L. Mean increase in BMI... In this small cohort, 61.5% of boys with CF between 8 and 9 years had an early rise of DHEAS, which was correlated to ΔBMI...